Renaissance Technologies’s INmune Bio INMB Stock Holding History

Renaissance Technologies’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.2K	Buy	+17,000	New	+$24.2K	﹤0.01%	3171
2025 Q1	–	Sell	-185,800	Closed	-$868K	–	3641
2024 Q4	$868K	Buy	185,800 +78,600	+73%	+$410K	﹤0.01%	2573
2024 Q3	$578K	Buy	+107,200	New	+$762K	﹤0.01%	2720
2023 Q3	–	Sell	-20,000	Closed	-$182K	–	3876
2023 Q2	$182K	Sell	20,000 -14,800	-43%	-$119K	﹤0.01%	3325
2023 Q1	$225K	Buy	+34,800	New	+$280K	﹤0.01%	3228
2022 Q3	–	Sell	-32,100	Closed	-$284K	–	4214
2022 Q2	$284K	Buy	+32,100	New	+$239K	﹤0.01%	3482
2020 Q4	–	Sell	-40,000	Closed	-$412K	–	3541
2020 Q3	$412K	Buy	+40,000	New	+$407K	﹤0.01%	2886

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies's INMB Position: Q1 2026 in Review

Renaissance Technologies opened a new position in INmune Bio (INMB) in Q1 2026: 17,000 shares worth $19.2K. The stake represents ﹤0.01% of the portfolio and ranks #3171 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in INMB as recently as Q4 2024.

Renaissance Technologies first reported a position in INMB in Q3 2020 and has held it in 7 quarters since. The position peaked at $868K in Q4 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

Renaissance Technologies held 17,000 shares of INmune Bio worth $19.2K as of Q1 2026.
INmune Bio was a new Renaissance Technologies position in Q1 2026.
INmune Bio made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #3171 holding.
Renaissance Technologies first reported a position in INmune Bio in Q3 2020 and has held it in 7 quarters since.
Renaissance Technologies's INmune Bio position peaked at $868K in Q4 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.